Tvardi Therapeutics Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
12
- Stock Symbol
-
TVRD
- Investments
-
1
- Share Price
-
$0.99
- (As of Friday Closing)
Tvardi Therapeutics General Information
Description
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
Contact Information
Website
www.tvarditherapeutics.comCorporate Office
- 3 Sugar Creek Center Boulevard
- Suite 525
- Sugar Land, TX 77478
- United States
Corporate Office
- 3 Sugar Creek Center Boulevard
- Suite 525
- Sugar Land, TX 77478
- United States
Tvardi Therapeutics Stock Performance
As of 20-Nov-2026, Tvardi Therapeutics’s stock price is $0.99. Its current market cap is $13.2M with 13.4M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.99 | $0.93 | $0.77 - $5.69 | $13.2M | 13.4M | 235K | -$2.63 |
Tvardi Therapeutics Financials Summary
As of 30-Sep-2026, Tvardi Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,054 | 4,108 | ||
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (27,500) | (19,494) | (30,049) | (18,570) |
| Net Income | (26,660) | (18,214) | (29,397) | (17,347) |
| Total Assets | 23,533 | 32,073 | 35,199 | 27,001 |
| Total Debt | 116 | 201 | 30,563 | 368 |
Tvardi Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Tvardi Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Tvardi Therapeutics Comparisons
Industry
Financing
Details
Tvardi Therapeutics Competitors (43)
One of Tvardi Therapeutics’s 43 competitors is Ayala Pharmaceuticals, a Corporation company based in Wilmington, DE.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| Innate Pharma | Formerly VC-backed | Marseille, France | ||||
| Gilead | Formerly VC-backed | Foster City, CA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Marengo Therapeutics | Venture Capital-Backed | Cambridge, MA |
Tvardi Therapeutics Patents
Tvardi Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025184497-A1 | Stat3 inhibitors for use in the treatment of cancer | Pending | 29-Feb-2024 | ||
| WO-2025137366-A2 | Solid-state forms of stat3 inhibitors and methods of use thereof | Inactive | 20-Dec-2023 | ||
| WO-2025137366-A3 | Solid-state forms of stat3 inhibitors and methods of use thereof | Inactive | 20-Dec-2023 | ||
| WO-2025054280-A1 | Formulations of stat3 inhibitors and methods of use thereof | Inactive | 05-Sep-2023 | ||
| WO-2024129619-A1 | Stat3 inhibitors for use in the treatment of non-viral liver cancer | Inactive | 12-Dec-2022 | A61K31/18 |
Tvardi Therapeutics Signals
Tvardi Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Tvardi Therapeutics Acquisitions (1)
Tvardi Therapeutics’s most recent deal was a Merger/Acquisition with Cara Therapeutics. The deal was made on 15-Apr-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Cara Therapeutics | 15-Apr-2025 | Merger/Acquisition | Drug Discovery |
Tvardi Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Tvardi Therapeutics FAQs
-
When was Tvardi Therapeutics founded?
Tvardi Therapeutics was founded in 2017.
-
Where is Tvardi Therapeutics headquartered?
Tvardi Therapeutics is headquartered in Sugar Land, TX.
-
What is the size of Tvardi Therapeutics?
Tvardi Therapeutics has 12 total employees.
-
What industry is Tvardi Therapeutics in?
Tvardi Therapeutics’s primary industry is Drug Discovery.
-
Is Tvardi Therapeutics a private or public company?
Tvardi Therapeutics is a Public company.
-
What is Tvardi Therapeutics’s stock symbol?
The ticker symbol for Tvardi Therapeutics is TVRD.
-
What is the current stock price of Tvardi Therapeutics?
As of 20-Nov-2026 the stock price of Tvardi Therapeutics is $0.99.
-
What is the current market cap of Tvardi Therapeutics?
The current market capitalization of Tvardi Therapeutics is $13.2M.
-
Who are Tvardi Therapeutics’s competitors?
Ayala Pharmaceuticals, Innate Pharma, Gilead, Kite Pharma, and Marengo Therapeutics are some of the 43 competitors of Tvardi Therapeutics.
-
What is Tvardi Therapeutics’s annual earnings per share (EPS)?
Tvardi Therapeutics’s EPS for 12 months was -$2.63.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process